1Sawamura T, Kume N, Aoyama T, et al. An endothelial, receptor for oxidized tow density lipoprotein. Nature, 1997,386:73- 77.
2Li D,Liu L,Chen HJ ,et al. LOX-1 mediates oxidized low density lipoprotein induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003,107:612-617.
3Chen K,Chen JW,Liu Y,et al. Adhesion molecule expression in fibroblasts alteration in fibroblast biology after transfection with LOX-1 plasmids. Hypertension,2005,46:622-627.
4Wolfgang K, Natalie K. Biomarkers of atheroscterotic plaque instability and rupture. Arterioscler Thromb Vasc Biot, 2007, 27:15-26.
5Heeschen C,Dimmel.er S, Harem CW, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med,2003,348:1104-1111.
6Kinlay S, Schwartz GG,Olsson AG, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIR ACL) Study investigators. Ettect ot atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation, 2004,110 : 386-391.
7Malarstig A, Lindaht B, Wal.l.entin L, et. al. Soluble CD40L levels are regulated by the 3,159A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non ST elevation acute coronary syndrome, Arterioscler Thromb Vasc Biol., 2006,2(3 : 1667-1673.
8Li D Y, Liu L,Chen HJ,et al. LOX-1,an oxidized LDI. endothelial receptor,induces C.D40/CD40L signaling in human coronary artery endothelial cells. Arteroscler Thromb Vasc Biol, 2003,23:816-821.
9Jiang DQ, Chu LX, Liu ZY, et al. Pioglitazone decreased CD40/CD40L expression on human umbilical vein cndothelial cells induced by oxidized low-density lipoprotein. Clin Chim Acta, 9006,370 : 94-99.
10Sakurai K, Cominacini L, Garbin U, et al. Induction of endothelin-1 production in endothelial, cells via co-operative action between CD40 and lectin-like oxidized LDL receptor (LOX-1). J Cardiovasc Pharmacol,2004,44:S173-S180.
5Mehta JL,Li DY.Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells.Biochem Biophys Res Commun,1998,248:511-514.
6Itabe H.Oxidative modification of LDL:its pathological role in atherosclerosis.Clin Rev Allergy Immunol,2009,37:4-11.
7Lubrano V,Del Turco S,Nicolini G,et al.Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers.Lipids,2008,43:945-950.
8Mehta JL,Chen J,Hermonat PL,et al.Lectin-like oxidized low-density[ipoprotein receptor-1(LOX-1):A critical player in the development of atherosclerosis and related disorders.Cardiovasc Res,2006,69:36-45.
9Chen XP,Zhang TT,Du GH.Lectin-like oxidized low-density lipoprotein receptor-1,a new promising target for the therapy of atherosclerosis? Cardiovasc Drug Rev,2007,25:146-161.
10Nakaya H,Summers BD,Nicholson AC,et al.Atherosclerosis in LDLR-knockout mice is inhibited,but not reversed by the PPARgamma ligand pioglitazone.Am J Pathol,2009,174:2007-2014.
